CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CG Oncology Inc (CGON) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company has promising clinical trials and analyst support, insider selling, limited revenue, and high dependency on future trial outcomes make it a risky investment. It is better to hold off until more concrete data or catalysts emerge.
The technical indicators show mixed signals. The MACD is below 0 and negatively contracting, suggesting bearish momentum. However, the RSI is neutral at 62.969, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of R1: 68.437, which could limit further upside in the short term.
Analysts have consistently raised price targets, with the most recent target at $90, citing promising clinical trial data for PIVOT-006 and a large addressable market.
Revenue growth in Q4 2025 was significant, up 409.21% YoY, showing some operational progress.
The company has $740 million in cash reserves, providing a strong financial cushion.
Insiders are selling heavily, with a 1311.54% increase in selling activity over the last month.
Kynam Capital recently sold a significant stake, reducing its position to 2.51%.
The company has only $4 million in annual revenue, making it highly dependent on future clinical trial success.
Gross margin dropped significantly to -32.21%, indicating operational inefficiencies.
In Q4 2025, revenue increased by 409.21% YoY to $2.32 million, but net income remained negative at -$41.31 million, albeit improving by 29.91% YoY. EPS improved to -0.52, up 13.04% YoY. However, gross margin dropped significantly to -32.21%, reflecting operational challenges.
Analysts are bullish on CGON, with multiple firms maintaining Buy ratings and raising price targets (e.g., UBS to $90, BofA to $72, H.C. Wainwright to $80). They highlight the potential of the PIVOT-006 trial and the large addressable market for bladder cancer therapies. However, the success is contingent on clinical trial outcomes expected in 1H26.
